Literature DB >> 22664836

Bone turnover markers: use in osteoporosis.

Kim Naylor1, Richard Eastell.   

Abstract

Biochemical markers of bone turnover (bone turnover markers, BTMs) can be used to study changes in bone remodelling in osteoporosis. Investigators and clinicians should be aware of the appropriate sample collection and storage conditions for optimum measurements of these markers. Improvements in the variability of BTM measurements have resulted from the development of assays for automated analysers, and from international consensus regarding their use. Appropriate reference intervals should be used for the optimum interpretation of results. BTMs can provide information that is useful for the management of patients with osteoporosis, for both the initial clinical assessment and for guiding and monitoring of treatment. BTMs are clinically useful to determine possible causes of secondary osteoporosis by identifying patients with high bone turnover and rapid bone loss. In the follow-up of treatment response, BTM levels respond rapidly to both anabolic and antiresorptive treatments. BTM changes can also be used for understanding the mechanism of action of drugs in development and identifying the correct dose; they are also potentially useful as surrogate biomarkers for fracture.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664836     DOI: 10.1038/nrrheum.2012.86

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  134 in total

1.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

2.  Effect of stopping risedronate after long-term treatment on bone turnover.

Authors:  Richard Eastell; Rosemary A Hannon; Dietrich Wenderoth; Jesus Rodriguez-Moreno; Andrzej Sawicki
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

3.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

Authors:  Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

4.  A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover.

Authors:  C Heuck; O D Wolthers
Journal:  J Endocrinol       Date:  1998-10       Impact factor: 4.286

5.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.

Authors:  P Garnero; E Sornay-Rendu; M C Chapuy; P D Delmas
Journal:  J Bone Miner Res       Date:  1996-03       Impact factor: 6.741

6.  Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.

Authors:  Alexandre Lapillonne; Rose Travers; Massimo DiMaio; Bernard L Salle; Francis H Glorieux
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

7.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.

Authors:  D R Eyre; T J Koob; K P Van Ness
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

8.  Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.

Authors:  S P Robins; H Woitge; R Hesley; J Ju; S Seyedin; M J Seibel
Journal:  J Bone Miner Res       Date:  1994-10       Impact factor: 6.741

9.  Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation.

Authors:  K E Naylor; A Rogers; R B Fraser; V Hall; R Eastell; A Blumsohn
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.

Authors:  Somnath Sarkar; Jean-Yves Reginster; Gerald G Crans; Adolfo Diez-Perez; Karen V Pinette; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2003-12-22       Impact factor: 6.741

View more
  78 in total

1.  Osteoporosis risk assessment using multilayered gold-nanoparticle thin film via SALDI-MS measurement.

Authors:  Xi-Yu Pan; Chih-Hwa Chen; Yi-Hsuan Chang; Di-Yan Wang; Yi-Cheng Lee; Chien-Chung Liou; Yu-Xian Wang; Cho-Chun Hu; Tsung-Rong Kuo
Journal:  Anal Bioanal Chem       Date:  2019-04-01       Impact factor: 4.142

2.  Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.

Authors:  X-Y Wu; H Zhang; H Xie; X-H Luo; Y-Q Peng; L-Q Yuan; R-C Dai; Z-F Sheng; X-P Wu; E-Y Liao
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

Review 3.  Bone remodeling markers and bone metastases: From cancer research to clinical implications.

Authors:  Arlindo Ferreira; Irina Alho; Sandra Casimiro; Luís Costa
Journal:  Bonekey Rep       Date:  2015-04-22

4.  Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

Authors:  A K Oestreich; S M Carleton; X Yao; B A Gentry; C E Raw; M Brown; F M Pfeiffer; Y Wang; C L Phillips
Journal:  Osteoporos Int       Date:  2015-07-16       Impact factor: 4.507

5.  Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors.

Authors:  Adetunji T Toriola; Jingxia Liu; Patricia A Ganz; Graham A Colditz; Lin Yang; Sonya Izadi; Michael J Naughton; Anna L Schwartz; Kathleen Y Wolin
Journal:  Breast Cancer Res Treat       Date:  2015-07-15       Impact factor: 4.872

Review 6.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 7.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 8.  Update on primary ovarian insufficiency.

Authors:  Meghan Hewlett; Shruthi Mahalingaiah
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-12       Impact factor: 3.243

9.  Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.

Authors:  L T Nguyen; U D T Nguyen; T D T Nguyen; L T Ho-Pham; T V Nguyen
Journal:  Osteoporos Int       Date:  2018-09-08       Impact factor: 4.507

10.  IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression.

Authors:  Sol Kim; Drake W Williams; Cindy Lee; Terresa Kim; Atsushi Arai; Songtao Shi; Xinmin Li; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2016-10-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.